PD-L1 Recombinant Rabbit Multiclonal Antibody - BSA and Azide free [PSH13-23] (HA751459)

UNIPROT #

Q9NZQ7

PROTEIN NAME

PD-L1

SYNONYMS

B7 H antibody;B7 H1 antibody;B7 homolog 1 antibody;B7-H1 antibody;B7H antibody;B7H1 antibody;CD 274 antibody;CD-274 antibody;CD274 antibody;CD274 antigen antibody;CD274 molecule antibody;MGC142294 antibody;MGC142296 antibody;OTTHUMP00000021029 antibody;PD L1 antibody;PD-L1 antibody;PD1L1_HUMAN antibody;PDCD1 ligand 1 antibody;PDCD1L1 antibody;PDCD1LG1 antibody;PDL 1 antibody;PDL1 antibody;Programmed cell death 1 ligand 1 antibody;Programmed death ligand 1 antibody;RGD1566211 antibody

SUBCELLULAR LOCATION

Cell membrane, Early endosome membrane, Recycling endosome membrane, Nucleus.

FUNCTION

PD-L1 (programmed-death ligand 1; CD274), is a transmembrane protein constitutionally expressed on a variety of cell types, including antigen presenting cells (dendritic cells and histiocytes) and some non-lymphoid tissues (heart and lung). Binding of PD-L1 to PD-1 (programmed-death 1; CD279) expressed by activated T-cells, inhibits their function, causing negative feedback control of immunological reactions, thus impeding inflammation and autoimmunity. Tumour cells may express PD-L1, which binds to PD-1 allowing cancer cells to evade the attack of T-cells. Blockade of the PD-1/PD-L1 pathway has now shown useful in therapy of multiple cancer types, causing durable tumour regressions in a substantial proportion of otherwise treatment refractory cases of melanoma, and carcinomas of e.g., lung, kidney, and urinary tract. Patients without tumour PD-L1 expression can also derive benefit from blocking agents (studies across multiple cancer types demonstrate a pooled response rate of 48% in patients with PD-L1-positive tumours compared to 15% in PD-L1-negative tumours). Tonsil and placenta can be used as positive and negative tissue controls. However, tonsil is found to be superior to placenta, as tonsil displayes a range of PD-L1 expression levels. Tonsil displayes the following reaction pattern: No staining reaction in the vast majority of lymphocytes including mantle zone and germinal centre B-cells, no staining reaction in superficial epithelial cells, a weak to moderate, typically punctuated membranous staining reaction of the majority of germinal centre macrophages and finally a moderate to strong staining reaction of the majority of epithelial crypt cells.